AIM Vaccine, which is accelerating the iteration and upgrade of rabies vaccines, has achieved new results in new product R&D. AIM Vaccine announced on November 17th that the company's independently developed serum-free iterative rabies vaccine has recently submitted a pre-application for market registration to the National Medical Products Administration.

On November 15th, the Center for Drug Evaluation, NMPA showed that the market registration of AIM Vaccine's developed 13-valent conjugate pneumonia vaccine was formally accepted. It is reported that AIM's 13-valent conjugate pneumonia vaccine adopts a single-carrier tetanus toxoid carrier technology route, which has higher yield compared to the diphtheria toxin carrier variant (CRM197) in the single-carrier protein route, and fewer production capacity factors compared to the dual-carrier route, possessing multiple competitive advantages.

Rabies vaccine giant AIM Vaccine announced on November 7th that the company's developed iterative high-efficacy human diploid cell rabies vaccine has submitted a clinical application to the Center for Drug Evaluation (CDE), NMPA. This means that AIM's strategic layout for the iteration and upgrading of rabies vaccines is accelerating its implementation. According to the announcement, AIM's iterative high-efficacy human diploid cell rabies vaccine demonstrates the iteration and upgrading of the product in many aspects.

AIM Vaccine announced on November 1st that the company's independently developed 13-valent conjugate pneumonia vaccine has submitted an application for drug market registration to the National Medical Products Administration. The group's wholly-owned subsidiary, AIM Persistence Biopharmaceutical Co., Ltd., has obtained the corresponding drug production license to produce this product. The launch of this vaccine is imminent, and after its launch, AIM will become an important global supplier of the 13-valent conjugate pneumonia vaccine, significantly enhancing the company's performance.

On October 30 that AIM Vaccine announced that the mRNA Respiratory Syncytial Virus (RSV) vaccine developed by the group's holding subsidiary has recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, marking a new stage in the development of the vaccine.

AIM Vaccine (06660.HK) announced on the evening of October 6 that the company and its subsidiaries (hereinafter collectively referred to as the "group") recently received a notice from the National Institutes for Food and Drug Control regarding the serum antibody detection results of the Phase III clinical trial of the serum-free iterative rabies vaccine. So far, the group's serum-free iterative rabies vaccine Phase III clinical trial data has completed unblinding and statistical analysis work. The study results show that the serum-free iterative rabies vaccine developed by the group has good immunogenicity and good safety, achieving the preset clinical targets.